Strata Critical Medical, Inc. is classed by the SEC under Services-Health Services (industry code 8000), based in New York, NY. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $197 million and a profit of $41 million (its filed statements).
Usage businessServices-Health ServicesNew York, NYfilings since 20198 of 9 filed, 1 estimated
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a usage business: prior from its industry code (SEC 8000, Services-Health Services); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 5.3 out of ten, 8 of 9 metrics filed and 1 estimated: past 4.6 out of ten, present 5.4 out of ten, future 5.8 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 5.3 out of ten. 3 warning events since 2019; the latest 2024-03-22. 53rd percentile among 15 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 4.0 out of ten. +34.3% a year over 7 filed years; profitable in 2 of 9. 40th percentile among 14 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Shareholder treatment (past): 4.6 out of ten. CrossAssetData estimate 4.6/10, confidence 35 of 100 (one part). 46th percentile among 14 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
Financial health (present): 6.6 out of ten. ROE 15%: 15¢ of profit per shareholder dollar. Leverage 14%: owes 14¢ per asset dollar. 66th percentile among 14 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 4.6 out of ten. bottom 46% of 14 in its family; net margin 21%. 46th percentile among 14 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 5.1 out of ten. top 49% of 10 in its family for leadership; chief executive since 2025. 51st percentile among 10 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
Room to expand (future): 2.8 out of ten. bottom 28% of 14 in its family for room to expand. 28th percentile among 14 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 5.3 out of ten. top 47% of 14 in its family for growth drivers. 53rd percentile among 14 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Expectations vs reality (future): 8.5 out of ten. top 15% of 12 in its family for expectations against reality. 85th percentile among 12 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-03-03 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-04 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-04 (on EDGAR). Newest filing: Form 144, 2026-10-02. Filings on record since 2019. Read from EDGAR 2026-10-12.
Where the revenue comes from
Lines of business in fiscal 2025: Logistics 90%, Clinical 10%. As tagged in its annual report (Form 10-K, filed 2026-03-03).
Who runs it
Heyburn, William A. (Co-CEO and CFO); Tomkiel, Melissa M. (Co-CEO and General Counsel); Verdetto, Louis R. (CEO, Clinical Services); Wunsch, Scott M (CEO, Logistics); Wiesenthal, Robert S (Chief Executive Officer); Affeldt, Eric (Chief Executive Officer); Cohen, Amir (Chief Accounting Officer); Love, Reginald (director); Cook, William L. III (director); Lauck, Andrew (director); and 4 more. 14 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.